Secondary Logo

Journal Logo

You can read the full text of this article if you:

Institutional members access full text with Ovid®

Original Articles: Genitourinary

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma

Real-world Data From an Italian Managed Access Program

Prisciandaro, Michele MD*; Ratta, Raffaele MD*; Massari, Francesco MD; Fornarini, Giuseppe MD; Caponnetto, Salvatore MD§; Iacovelli, Roberto MD; De Giorgi, Ugo MD; Facchini, Gaetano MD#; Scagliarini, Sarah MD**; Sabbatini, Roberto MD††; Caserta, Claudia MD‡‡; Peverelli, Giorgia MD*; Mennitto, Alessia MD*; Verzoni, Elena MD*; Procopio, Giuseppe MD*

Author Information
American Journal of Clinical Oncology: January 2019 - Volume 42 - Issue 1 - p 42-45
doi: 10.1097/COC.0000000000000478

Abstract

Erratum

In “Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program,” which published in the January 2019 issue, the authors would like to make a few corrections. In the background it was wrongly stated that in the METEOR trial the median progression free survival (mPFS) of Everolimus was 3.08 months, but actually the real mPFS of everolimus arm was 3.8 months.

In the treatment section and within the abstract, it was stated that Cabozantintib was administered in a 28 days cycles whereas its labeled administration is in continuous treatment. Furthermore, it was specified: “A lower starting dose of 40 mg were prescribed in patients in worse clinical conditions with a dose escalation to 60 mg in case of good tolerance.” Actually, dose re-escalation must be considered as off-lable use of the drug.

Moreover, in the results section data were wrongly reported: the sentence “  ” should read “  ; the sentence “” should read “”; the sentence “” should read “”. In Table 1 the line “” should read “”.

American Journal of Clinical Oncology. 42(4):412, April 2019.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.